Well, for one thing, I find the complete lack of research interest in Taiwan … disturbing. You would think somebody might want to know precisely why Taiwan has been so (apparently) successful, despite the fact that other countries have followed similar paths with rather more variable outcomes. Handwaving about masks etc and saying “of course it’s because of this and that” isn’t very scientific. Those are falsifiable hypotheses, but I can’t find anything about testing those hypotheses as they relate to Taiwan, specifically.
Here’s one of the papers I mentioned:
https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(20)30041-9/fulltext
… which itself observes, with suitable deadpan:
“We searched PubMed for peer-reviewed articles and preprint reports on “seroprevalence”, “SARS-CoV-2 antibody”, “anti-SARS-CoV-2”, and similar terms, up to August 31, 2020. There were only a few and most serological studies focused on specific subpopulation in “hotspot” regions of the world. Additionally, in most serological studies only one single type of laboratory test was performed, which might generate more false positive results and over-estimate the prevalence of anti-SARS-CoV-2 antibodies.”
In other words, nobody has really bothered looking at the Taiwan situation, and of those who did, they didn’t do a very good job.
Now, simply being published in The Lancet doesn’t mean this study is worth anything, but I’ve had a scan through and I can’t see any obvious reason to dismiss it out-of-hand. They’ve taken pains to measure and correct for false positives.
0.05% is lower than the figure I mentioned earlier, but this is a representative population, so it’s not unreasonable to extrapolate that out to “10,000 people in Taiwan have at some point contracted COVID-19”. Note only one significant figure in that statement. Note also that this study was back in May 2020, and that was a long time ago. As mentioned, nobody seems to have bothered to do anything since then … unless anyone here knows differently?